

Haematologica
HAEMATOL/2016/153957
Version 3

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Nicola Gökbuget, Gerhard Zugmaier, Matthias Klinger, Peter Kufer, Matthias Stelljes, Andreas Viardot, Heinz A. Horst, Svenja Neumann, Monika Brüggemann, Oliver G. Ottmann, Thomas Burmeister, Dorothea Wessiepe, Max S. Topp, and Ralf Bargou

Disclosures: This work was supported by Amgen Inc. Disclosures for individual authors are as follows. NG: Speaker and advisory board honoraria from Amgen and Pfizer. Research support from Amgen. GZ: Employee of Amgen (Research) Munich GmbH and shareholder in Amgen Inc. MK: Employee of Amgen (Research) Munich GmbH and shareholder in Amgen Inc. Inventor on patents related to blinatumomab. PK: Employee of Amgen (Research) Munich GmbH and shareholder in Amgen Inc. Inventor on patents related to blinatumomab. Recipient of royalties on blinatumomab product sales. AV: Amgen (Honoraria, Advisory Board); Janssen (Honoraria, Advisory Board); Gilead (Advisory Board); Roche (Honoraria); BMS (Advisory Board); Pfizer (Honoraria). MST: Amgen (honoraria, consulting, research funding, and travel expenses). RB: Fees from Amgen, Novartis, Astra Zeneca, and GEMoaB, and a patent for blinatumomab with royalties paid. MS, HAH, SN, MB, OGO, TB, DW: None

Contributions: All authors contributed to the research. DW performed the statistical analysis. MK performed the T-cell analysis. NG and GZ wrote the draft manuscript with contributions from all authors. All authors approved the final manuscript.